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Mutations in the connection subdomain (CN) and RNase H domain (RH) of HIV-1 reverse transcriptase
(RT) from subtype B-infected patients enhance nucleoside and nonnucleoside RT inhibitor (NRTI and
NNRTI) resistance by affecting the balance between polymerization and RNase H activity. To determine
whether CN mutations in subtype C inﬂuence drug sensitivity, single genome sequencing was
performed on Brazilian subtype C-infected patients failing RTI therapy. CN mutations identiﬁed were
similar to subtype B, including A376S, A400T, Q334D, G335D, N348I, and A371V, and increased AZT
resistance in the presence of thymidine analog mutations. CN mutations also enhanced NNRTI
resistance in the presence of classical NNRTI mutations: etravirine resistance was enhanced 6- to 11-
fold in the presence of L100I/K103N/Y181C. These results indicate that selection of CN mutations in
treatment-experienced patients also occurs in subtype-C-infected patients and are likely to provide
valuable information in predicting clinical RTI resistance.
Published by Elsevier Inc.Introduction
Human immunodeﬁciency virus type 1 (HIV-1) is the causative
agent of the global AIDS pandemic and is subdivided into four
major groups: M (Main), O (Outlier), N (Non-M/O), and the recently
described group P (Plantier et al., 2009). Group M is responsible for
495% of all HIV infections worldwide and is comprised of nine
different subtypes: A, B, C, D, F, G, H, J, and K (Robertson et al.,
2000), in addition to 49 intersubtype recombinants designated
circulating recombinant forms (CRFs) (http://www.hiv.lanl.gov/).
HIV-1 epidemiological surveys show that subtype C accounts for
48% of infections globally and is found mainly in southern Africa
and India (Hemelaar et al., 2011). Subtype B is found predominantly
in the western world, and despite accounting for only 11% of HIV-1Inc.
Drug Resistance Program,
, Building 535, Room 334,
lobo.com (A.F. Santos),
ia.ufrj.br (M.A. Soares),
nih.gov (F. Maldarelli),infections, this subtype remains the major model subtype from
which data is collected to develop antiviral drugs, identify drug
resistance mutations and determine drug treatment regimens.
Sequence diversity within subtype B ranges from 10–30 %,
while sequence diversity within subtype C ranges from 5–15 %
(Gaschen et al., 2002). These inherent differences are due to
naturally occurring nucleotide polymorphisms which can impact
not only drug resistance and viral ﬁtness, but also potential
vaccine success. In general, the HIV-1 subtypes have been shown
to respond similarly to standard drug therapy and acquire similar
drug resistance mutations, suggesting that in most cases analyses
compiled with subtype B can be extended to other subtypes
(Alexander et al., 2002; Frater et al., 2002; Geretti et al., 2009;
Kantor et al., 2005; Palmer et al., 1998; Pillay et al., 2002).
However, numerous reports have also shown that intersubtype
diversity can inﬂuence the effectiveness of antiviral therapy
[reviewed in (Santos and Soares, 2010)]. Genetic differences
between the HIV-1 subtypes can alter the response to certain
antiviral drugs, the pathway and speed of acquiring resistance,
the drug mutational pattern, the level of drug resistance, and the
overall viral replicative capacity (Abecasis et al., 2005; Brenner
et al., 2003; Brenner et al., 2006; Caride et al., 2001; Grossman
et al., 2004; Holguin et al., 2006; Lai et al., 2010; Martinez-Cajas
et al., 2009; Palmer et al., 1998; Soares et al., 2007). Therefore, it is
K.A. Delviks-Frankenberry et al. / Virology 435 (2013) 433–441434important to understand the emergence of drug resistance in
non-B subtypes to develop different drug strategies and better aid
those patients not responding to therapy.
Reverse transcriptase (RT) is composed of the polymerase
domain (POL) which includes the ﬁngers, palm, thumb, and
connection subdomains (CN) as well as the RNase H domain
(RH) (di Marzo Veronese et al., 1986; Lowe et al., 1988), with RT
drugs targeting POL to block DNA polymerization during reverse
transcription. Analysis of patient drug resistance is usually con-
ﬁned to the ﬁrst 300 amino acids of POL (Johnson et al., 2010;
Martinez-Cajas et al., 2008), leaving the C-terminal domain of RT,
which includes the CN and RH, largely understudied for drug
resistance mutations. We have previously reported that drug
resistance mutations C-terminal to POL can also signiﬁcantly
increase resistance to both nucleoside and non-nucleoside
reverse transcriptase inhibitors (NRTIs and NNRTIs, respectively)
(Delviks-Frankenberry et al., 2010; Nikolenko et al., 2007;
Nikolenko et al., 2010). Analysis of RT C-terminal domains from
seven treatment-experienced subtype B-infected patients showed
that the patient-derived CNs increased AZT resistance by as much
as a 500-fold in the context of TAMs (Nikolenko et al., 2007). Eight
novel mutations, E312Q, G335C/D, N348I, A360I/V, V365I, and
A376S, were identiﬁed within the CN of RT that signiﬁcantly
contributed to AZT resistance, and these mutations were further
found to decrease RNase H activity, leading to decreased suscept-
ibility to AZT (Delviks-Frankenberry et al., 2008; Nikolenko et al.,
2007; Nikolenko et al., 2005).
We further analyzed 450 subtype B isolates from the Stanford
University HIV Drug Resistance Database and showed that 9 CN
mutations (I326V, R358K, G359S, A360T, A360V, K366R, A371V,
K390R and A400T) and 6 RH mutations (I506L, K512R, K527N,
K530R, and Q457K) were positively associated with NRTI or
AZT monotherapy exposure (Santos et al., 2008). The recent
OPTIMA trial also identiﬁed CN mutations Y318F, G333D/E,
G335D, N348I, V365I, A371V and A376S as positively associated
with treatment experience in a 345 subtype-B-infected patient
cohort (Dau et al., 2010). Associations of these and other CN
mutations with drug exposure and TAMs has also been conﬁrmed
through other subtype-B-infected patient cohorts and in vitro stu-
dies (Cane et al., 2007; Dau et al., 2010; Ehteshami et al., 2008;
Gupta et al., 2010; Hachiya et al., 2008a; Lengruber et al., 2011;
Michels et al., 2010; Price et al., 2010; von Wyl et al., 2010a; von
Wyl et al., 2010b; Waters et al., 2009; Yap et al., 2007) Recently, CN
mutation A360V was shown to be selected in subtype-B-infected
patients receiving AZT monotherapy (Brehm et al., 2012b).Fig. 1. Patient genotypic proﬁles. (A) The polymerase domain (POL), connection subdom
(P1, P2, P3, and P5) compared in this study are shown. P1 is subtype B (white boxes), P2
RT up to amino acid 375 subtype B, and the remainder subtype C. (B) Major NRTI, NN
(C) Amino acid alignment of the HIV-1 RT CN (amino acids 312–425) for each patient,
consensus sequence (BRZ; consensus of Brazilian subtype C’s AF286228, AY727522, AY
alignment. CN mutations previously identiﬁed to be associated with drug resistance inThe contribution of RT C-terminal domain mutations in non-B
subtypes remains to be determined. We have previously reported
that CN mutation A400T in CRF01_AE is an important determinant
for AZT resistance in CRF01_AE patients containing TAMs (Delviks-
Frankenberry et al., 2009). Recent data from the Lampang Cohort of
CRF01_AE patients failing d4T, 3TC and NVP therapy showed that CN
mutations N348I and E399D were associated with treatment failure
(Saeng-aroon et al., 2010), and in vitro studies for CRF01_AE viruses
containing N348I and A371V in the presence of TAMs also showed
enhanced NRTI drug resistance (Tanuma et al., 2010). Additionally, a
cohort of treatment-naı¨ve patients from Mali, West Africa, 71% of
whom where CRF02_AG, showed a high prevelance for CN poly-
morhisms A371V (63%), G335D (76%) and E399D (11%) (Haidara
et al., 2010). Furthermore, 10% of treatment naı¨ve subtype C-infected
patients from Southern Brazil were shown to already contain CN
mutations (for example, T369I and A376S) (Santos et al., 2011),
suggesting that drug therapy may already be compromised in
patients harboring CN polymorphisms associated with drug treat-
ment. Together, these data suggest that other HIV-1 subtypes and
CRFs may also contain CN mutations that inﬂuence drug resistance.
Therefore, the aim of this paper was to determine whether subtype-
C-infected patients also acquire CN mutations in response to drug
therapy, whether the CN mutations differ from those reported from
subtype B, and whether the CN mutations contribute to enhanced
drug resistance in the background of a subtype C genotype.Results
Characterization of RT mutations present in subtype C-infected
patients
Since subtype C accounts for the majority of HIV-1 infections
worldwide, we sought to determine whether mutations in the CN
of subtype C-infected patients would also inﬂuence RTI drug
resistance. Fig. 1A shows schematically the RT region of the four
treatment-experienced patients analyzed in this study. We
included a subtype B treatment-experienced patient (P1) from
Brazil for comparison to the two treatment-experienced Brazilian
subtype C-infected patients, P2 and P5. Patient P3, a B/C recom-
binant was also included in the analysis as B/C recombinants are
prevalent in southern Brazil due to the high proportions of
patients infected with subtype B and/or subtype C isolates in that
population (Soares et al., 2005; Soares et al., 2003). SimPlot
analysis of the RT region (data not shown) conﬁrmed that P1 isain (CN) and RNase H domain (RH) of the four RTI treatment-experienced patients
and P5 are subtype C (gray boxes), and P3 contains a chimeric RT with the 50 half of
RTI, and CN mutations for each patient identiﬁed by single genome sequencing.
for subtype C reference strain MJ4 from Cameroon and for the Brazilian subtype C
727523, AY727524, AY727525). Subtype B pNL43 serves as the reference strain for
subtype B are indicated in bold.
BB
CNPOL RH
B
BBTAMs B 18X
C
D67N, K70R, T215Y, K219Q
CNPOL RH
CNPOL RH
K.A. Delviks-Frankenberry et al. / Virology 435 (2013) 433–441 435subtype B, P2 and P5 are subtype C, and P3 contains a chimeric RT
(Fig. 1A) with the POL and the CN up to amino acid 375 from
subtype B and the remainder of the CN and RH from subtype C.
The major POL and CN mutations associated with each patient
are shown in Fig. 1B. All patients received AZT and 3TC treatment,
and the inclusion of 3TC resulted in the selection of the M184V
mutation. P3 and P5 also received EFV treatment, which was
associated with the selection of the NNRTI POL mutations L100I
and K103N. P1 and P2 did not receive any NNRTIs, however they
were treated with protease inhibitor NFV, with P2 also receiving
ATV/R treatment. Standard TAMs (M41L, D67N, L210W, F214L,
T215F/Y, K219N/E), were observed in POL, with P1 lacking NRTI
TAMs. Alignment of the CN amino acid sequence (Fig. 1C) showed
that each patient had a unique pattern of CN mutations. Interest-
ingly, the CN mutations observed in the subtype-C-infected
treatment-experienced patients were similar to those previously
identiﬁed in subtype B: P2, G335D and N348I; P3, Q334D, A371V,
A376S, and A400T; and P5, G335D and A371V. Subtype B patient
P1 also contained previously identiﬁed CN mutations A376S and
A400T. Thus, similar CN mutations as subtype B are associated
with RTI therapy of subtype C-infected patients.
We further analyzed the prevalence of these CN mutations in
subtype-C naı¨ve and treatment-experienced patients from the Stan-
ford University HIV Drug Resistance Database (http://hivdb.stanford.
edu) (Table 1). Mutation Q334D, G335D, N348I, and A371V were
found to be signiﬁcantly associated with subtype-C-infected
treatment-experienced patients. Database analysis showed A400T
to be a common polymorphism in subtype C, while N348I (15%)
and A371V (14%) were positively associated with RTI treatment.
Interestingly, Q334D and G335D were negatively associated with
treatment (Q334D: 11% naı¨ve vs. 3.5% treated, G335D: 81% naive vs.
56% treated).CCTAMS C
CC C
CB B
CBTAMs B
28X
18X
D67N, K70R, T215F, K219Q
AZT  EC     (µM)
Fig. 2. AZT resistance associated with the wild-type subtype C RT and CN.
(A) Schematic representation of the subtype B HIV-1 luciferase-expressing vector
used for antiviral drug resistance and for generating chimeric viruses. pHL[B-WT],
white boxes and pHL[C-WT], gray boxes. (B) AZT resistance associated with
subtype B and subtype C RTs in the presence or absence of TAMs. (C) AZT
resistance associated with the subtype C CN in the background of subtype B in the
presence or absence of TAMs. Error bars represent the standard error of the mean
of at least two replicates from three independent experiments. Increases in drug
resistance are indicated relative to wild-type subtype B (one-fold, deﬁned as 1 ).
LTR, long terminal repeat, PRO, protease. POL, CN and RH are the polymerase
domain, connection subdomain and RNase H domain of RT, respectively.RT and CN from subtype-C and subtype-B exhibit similar levels of AZT
resistance
To test for drug resistance, vectors were created by inserting the
POL, CN and RH from wild-type subtype C into pHL[B-WT] to create
pHL[C-WT] (Fig. 2A). These two basic vectors (referred to as B-WT
and C-WT) were used to create additional chimeric POL, CN, and/or
RH vectors containing subtype B, subtype C and/or patient RT
sequences. Any reference to ‘‘wild type’’ refers to the prototype
subtype strain pNL4-3 for subtype B and MJ4 for subtype C.
Inherent levels of AZT resistance were ﬁrst tested for wild-type
subtype C in the absence (C-WT) or presence (C-TAMs) of TAMs
(D67N, K70R, T215F/Y and K219Q). No signiﬁcant differences in the
50% effective concentration [EC50] for AZT were observed between
B-WT (EC50¼0.05 mM; 1 ) and C-WT (EC50¼0.06 mM; 1 )
(Fig. 2B). Slight increases in the AZT EC50 were observed between
subtype B (18 ) and C (28 ) in the presence of TAMs, however
this is likely due to the fact that the subtype B TAMs combination
contained mutation T215Y instead of T215F. We have previouslyTable 1
Prevalence of CN mutations in subtype C-infected patients in Stanford University HIV
Mutation Treatment naı¨ve RTI tr
Total no. of CN
mutations
Total no. of CN
sequences
% CN
mutations
Total
mutat
Q334D 164 1465 11 5
G335D 1067 1322 81 57
N348I 2 1191 0.2 9
A371V 35 1131 3 8
A376S 50 1110 5 2
A400T 607 993 61 20shown that the difference in AZT resistance between TAMs combi-
nation D67N, K70R, T215Y and K219Q versus D67N, K70R, T215F
and K219Q in a subtype B background is 1.6-fold (Nikolenko
et al., 2007). Thus the 28-fold increase in resistance for C-TAMs
versus the 18-fold increase in resistance for B-TAMs is likely due to
the T215F amino acid change (resulting increase also 1.6-fold).
We further tested the wild-type subtype C CN in the background
of subtype B to test for any inherent AZT resistance associated with
the subtype C wild-type CN (Fig. 2C). The addition of the subtype-C
CN to B-WT did not change the baseline AZT resistance either in
the absence (EC50¼0.04 mM; 1 ) or presence of TAMs (EC50¼
0.92 mM; 18 ). Therefore, subtype-B and subtype-C RTs have
similar baseline levels of AZT resistance and no inherent poly-
morphisms in the MJ4 subtype-C CN alter that resistance.RT from subtype-C treatment-experienced patients P2, P3 and P5
exhibit enhanced AZT resistance.
To test the levels of drug resistance associated with each
patient, vectors were created in which the POL, CN and RH fromDrug Resistance Database.
eated Chi-Square/
Fisher’s
no. of CN
ions
Total no. of CN
sequences
% CN
mutations
142 4 0.0024
102 56 0.0070
62 15 o0.0001
56 14 0.0006
57 4 1.0000
30 67 0.5751
CNPOL RH
CCTAMS C
P1     P1 P1
P2
PA     PA PA
     P2 P2
P3     P3 P3
55 5
P1     CTAMS C
P2     CTAMS C
P3     CTAMS C
P5     CTAMS C
28X
CC C
153X
78X
51X
58X
1X
48X
60X
P1     CTAMS C
P2     CTAMS C
P3     CTAMS C
P5     CTAMS C
15X
S376A, T400A
D335G, I348N
D335G, V371A
D334Q, V371A, S376A, T400A
18X
33X
8X
15X
AZT  EC     (µM)
Fig. 3. AZT resistance associated with patient subtype C CNs. (A) AZT resistance
associated with the entire RT isolated from three subtype-C-infected patients (P2,
P3, P5) and one subtype B patient (P1) (black boxes). Wild-type subtype C AZT
resistance in the presence or absence of TAMs serves as a reference (gray boxes).
(B) AZT resistance associated with each patient’s CN in the presence of a subtype C
TAMs-containing POL. (C) AZT resistance levels associated with revertant muta-
tions (indicated as thin gray lines with amino acid position below labeled with an
‘‘x’’) for each patient’s CN in the presence of TAMs. Error bars represent the
standard error of the mean of at least two replicates from three independent
experiments.
CNPOL RH
CCTAMS C
T400A
CTAMS C
CB B
B B
CBTAMs B
BTAMs B
10X
28X
18X
T400A
T400A
10X
AZT  EC     (µM)
Fig. 4. AZT resistance associated with amino acid 400 in subtype C RT. Level of
resistance associated with amino acid conversion T400A in (A) subtype C RT
containing TAMs or (B) the subtype C CN in the background of wild-type or TAMs-
containing subtype B. Increases in drug resistance are indicated relative to wild-
type subtype B (one-fold, deﬁned as 1 ). Error bars represent the standard error
of the mean of at least two replicates from three independent experiments.
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overall level of AZT resistance associated with the entire POL, CN
and RH from each patient in reference to C-WT . For P1, the level
of AZT resistance was 1 (EC50¼0.03 mM), likely due to the
absence of TAMs in this patient’s POL. P2 and P3 exhibited higher
levels of AZT resistance (48 and 60 , respectively), while P5
exhibited similar levels of resistance (15 ) to the subtype-C
TAMs background (28 ). The overall AZT resistance levels are a
reﬂection of the unique combinations and interactions of muta-
tions present in the POL, CN and RH of each patient.
Increase in AZT resistance associated with subtype C-infected
treatment-experienced patients is localized to the CN
Since mutations in POL, especially L74V and M184V, can
counteract AZT resistance levels (Boyer et al., 2002; Frankel
et al., 2005; Gotte et al., 2000; Miranda et al., 2005), additional
vectors were created in which the patient CNs were subcloned
into pHL[C-TAMs]. This way the level of resistance associated
with each patient CN could be evaluated in the context of the
same POL genotype. We have previously shown that subtype-B
and CRF01_AE mutations in the CN can increase AZT resistance
above the TAMs background (Delviks-Frankenberry et al., 2009;
Nikolenko et al., 2007). As shown in Fig. 3B, for patients P1, P2, P3and P5, each CN was associated with increases in AZT resistance
up to 153 , 78 , 51 , and 58 , respectively. This increase in
resistance was above the C-TAMs background (28 ), and shows
that the mutations present in the subtype-C-infected patient CNs
(P2, P3, P5) as well as subtype-B-infected patient CN (P1) exhibit
enhanced resistance to AZT. Interestingly, patient P1 which
showed no increase in AZT resistance with its entire RT, exhibited
a 153 increase in AZT resistance associated with its CN. This
result likely shows the power of the M184V mutation in POL to
counteract AZT resistance, as previously reported (Boyer et al.,
2002; Gotte et al., 2000; Nikolenko et al., 2007). However, the
resistance proﬁle for patient P1 is likely more complex and cannot
be explained by the effect of M184V alone, as patients P2, P3 and
P5 also contained M184V and exhibited increases in AZT resis-
tance (Fig. 3B).
To verify whether the CN mutations were responsible for the
increase in AZT resistance, CN revertant mutants were generated
in which key amino acids previously associated with increased
AZT resistance were replaced with amino acids not associated
with resistance. These revertant mutants were generated for each
patient’s CN and tested for AZT resistance (Fig. 3C). The revertant
mutants reduced AZT resistance levels on average 4- to 6-fold,
back to levels similar to the C-TAMs background (28 ). Fold
changes in AZT resistance dropped from 153 to 33 for P1,
78 to 18 for P2, 51 to 8 for P3, and 58 to 15 for P5,
suggesting that these CN mutations in the subtype C context do
contribute to AZT resistance.
Amino acid T400 in subtype C contributes to AZT resistance
The role of the A400T polymorphism in subtype C was also
investigated, as it was previously shown that this same CN
polymorphism in CRF01_AE played a signiﬁcant role in AZT
resistance; the T400A revertant mutant reduced AZT resistance
11-fold in wild-type CRF01_AE (Delviks-Frankenberry et al.,
2009). Fig. 4A shows that changing the T400 to alanine in the
context of C-TAMs, reduced the level of AZT resistance 2.8-fold.
When the subtype C CN was cloned into B-TAMs, converting the
T400 to alanine resulted in a 1.8-fold reduction in AZT resistance
(Fig. 4B), similar to that seen in the background of C-TAMs . No
change was observed in a wild-type B background. Overall, this
data suggests a small role for T400 in contributing to the overall
drug resistance associated with C-TAMs . This was in agreement
CNPOL RH
CCTAMS C
P1     P1 P1
P2
PA     PA PA
     P2 P2
P3     P3 P3
55 5
P1     CTAMS C
P2     CTAMS C
P3     CTAMS C
P5     CTAMS C
CC C
BBTAMS B
BB B
NRTI NNRTI
AZT d4T 3TC TDF EFV NVP DLV ETR
1 1 1 1 1 1 1 1
18 2.2 2.6 2.0 0.6 0.5 0.8 0.8
1 1.1 0.9 0.8 0.9 0.6 1.1 0.8
28 1.4 2.3 1.8 0.4 0.4 1.3 0.4
CCTAMS C 28 1.4 2.3 1.8 0.4 0.4 1.3 0.4
1 0.8 >29 0.6 1.9 3.4 5.5 3.9
48 1.3 >29 2.7 0.5 1.3 1 0.4
60 1.8 >29 3.0 >6 >357 >6.5 >12
15 1.2 >29 1.3 >6 >71 >6.6 >12
153 2.4 1.7 5.2 2.1 0.3 2.6 1.3
78 1.0 1.3 2.9 0.7 0.6 1.4 0.9
51 1.1 1.5 2.7 0.7 0.6 0.9 0.2
58 1.8 7.2 1.7 0.9 1.0 1.7 0.7
*
*
*
*
*
*
*
*
*
* *
*
*
# ##
Fig. 5. NRTI and NNRTI resistance associated with patient-derived subtype C RTs
and CNs. Shown are the NRTI and NNRTI drug resistance levels for (A) reference
subtype-B and subtype-C RTs in the presence or absence of TAMs, (B) patient-
derived subtype-C RTs and (C) CNs in the presence of a subtype C RT containing
TAMs. Increases in drug resistance are indicated relative to wild-type subtype B
(one-fold, deﬁned as 1 ). n, Signiﬁcant fold increases (t-test: Po0.05) in drug
resistance compared to subtype C-TAMs control. #, Signiﬁcant fold increases in
drug resistance compared to B-TAMs control.
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treatment-naı¨ve and RTI treated subtype C-infected patients,
61% and 67%, respectively (Table 1).
Subtype-C CN mutations enhance resistance to other NRTIs and
NNRTIs in the context of TAMs
The HIV-1 vectors containing subtype-C CNs were also tested
for increases in drug resistance to NRTIs d4T, 3TC, and TDF, as
well as NNRTIs EFV, NVP, DLV, and ETR. Fig. 5 summarizes the
levels of drug resistance with all fold changes normalized to B-WT
for reference (see Supplementary Fig. 1 for detailed EC50 data). For
the entire RT (Fig. 5A), subtype B and subtype C in the presence or
absence of TAMs had similar levels of drug resistance. The
increase in AZT resistance associated with C-TAMs (28 ) versus
B-TAMs (18 ) was statistically signiﬁcant (P¼0.04), as was
resistance to DLV (0.8 to 1.3 ) and ETR (0.8 to 0.4 )
(P¼0.04 and 0.02, respectively). The entire RTs obtained from
subtype-C-infected patients (Fig. 5B) showed variable levels of
resistance depending upon the NRTI and/or NNRTI drug mutation
combinations present in their respective POL in addition to effects
of CN and/or RH mutations. Fig. 5C shows the levels of drug
resistance associated with each patient’s CN in the presence of C-
TAMs so that they can be evaluated in the context of the same
POL genotype. P1, P2, P3, and P5 all showed signiﬁcant increases
in AZT drug resistance (Po0.003) compared to C-TAMs (data
described previously in Fig. 3B). Even though P2 and P3 contain
N348I and A369V, CN mutations previously shown to potently
increase AZT resistance in a WT pol background (2–5 fold and
9 fold, respectively) (Gupta et al., 2010; Hachiya et al., 2008a;
Hachiya et al., 2009; Lengruber et al., 2011; Yap et al., 2007), their
resistance levels were still lower than P1 in the presence of TAMs.
This suggests that it is hard to predict the phenotype based upon
individual CN mutations and how they will interact with other
mutations. Patient P1 also showed signiﬁcant increases in d4T
resistance, and P1 and P2 showed signiﬁcant increases in TDFresistance (Po0.05). Interestingly, even in the presence of TAMs,
small signiﬁcant increases in NNRTI drug resistance were seen
with P1, P2 and P5 for EFV (Po0.04), P1 for DLV (P¼0.04), and P1
and P2 for ETR (Po0.03). Thus, CN mutations in a subtype-C
genetic background also increased NNRTI resistance above the
TAMs background.
CNs from subtype C enhance NNRTI drug resistance in the context of
classical NNRTI resistance mutations
Since TAMs are not normally selected in response to NNRTIs,
NNRTI resistance associated with each patient’s CN was further
evaluated by constructing vectors in which the patient’s CN was
paired with a subtype-C POL domain containing mutations that
increase NNRTI resistance, speciﬁcally either L100I, K103N, Y181C,
G190A, or L100IþK103NþY181C (Fig. 6). These vectors were tested
for NVP, DLV, EFV or ETR resistance compared to C-WT (see
Supplementary Fig. 2 for detailed EC50 data). The mutations present
in each patient’s CN signiﬁcantly enhanced resistance to NVP, DLV,
and EFV in the context of these classical NNRTI resistance mutations.
G190A is not normally associated with DLV resistance (Huang et al.,
2003), so only small increases in resistance were observed with the
addition of CNs from P2, P3 and P5 (2–3 ); however P1 did exhibit
a modest 6 increase above reference background (C-G190A,
1.4 ). For the most recently approved potent NNRTI ETR, the patient
CNs were still able to enhance resistance in the background of single
POL mutants, except for K103N which is not a resistance mutation
for ETR (Johnson et al., 2010). P1 CN however was able to increase
resistance 3-fold over the K103N background for ETR. Even more
impressive are the results with the triple POL mutant containing
L100IþK103NþY181C: all four patients’ CNs could still enhance
resistance 6 to 25-fold above the background ETR resistance (40 ).
Overall, these results indicate that CN mutations from subtype-C-
infected patients can contribute to both NRTI and NNRTI resistance.Discussion
The role of CN mutations in contributing to overall virological
failure remains under debate, and additional genotypic and pheno-
typic resistance studies with larger patient cohorts are needed
(Brehm et al., 2012a; Brehm et al., 2011; Gupta et al., 2011; Hachiya
et al., 2009; von Wyl et al., 2010a). In this report we examined the
contribution of CN mutations to drug resistance from subtype-C-
infected patients failing drug therapy. We conﬁrm that the subtype-
C-infected patients (P2, P3, P5), just like the subtype-B-infected
patient (P1), acquired mutations in the CN of RT that can inﬂuence
RTI resistance. The mutations observed with our subtype-C cohort,
A376S, A400T, Q334D, G335D, N348I, and A371V, were similar to
those previously reported for subtype B. No new CN mutations
were identiﬁed for subtype C; however, even with the limited
cohort size, six of the commonly recognized CN mutations were
present amongst these patients. Stanford University HIV Drug
Resistance Database analysis conﬁrmed that three of the identiﬁed
CN mutations, G335E, N348I and A371V were positively associated
with subtype-C treatment-experienced patients. In agreement with
these results, Brehm et al. recently reported that N348I was
signiﬁcantly increased in subtype-C-infected patients failing ther-
apy, and was associated with enhanced resistance to EFV, NVP, ETR
and AZT (Brehm et al., 2012a).
Overall, there was no inherent difference in resistance levels
between wild-type subtype B and wild-type subtype C, indicating
that their RTs have similar sensitivities to RT inhibitors. This is in
agreement with in vitro biochemical data in which both subtype-
B and -C RTs have been shown to have similar RT activity, drug
susceptibility and RNase H cleavage (Xu et al., 2010). We also did
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Fig. 6. NNRTI drug resistance associated with patient-derived CNs from subtype C.
(A) Increases in NNRTI drug resistance are reported relative to the wild-type
subtype C for each NNRTI (n, one-fold, deﬁned as 1 ). NVP, DLV, EFV and ETR drug
resistance levels for each patient’s CN in the background of a NNRTI-containing
POL are indicated: (B) L100I, (C) K103N, (D) Y181C, (E) G190A, and
(F) L100IþK103NþY181C. Signiﬁcant increases in drug resistance (Po0.05) for
each patient’s CN relative to the baseline vector containing the NNRTI POL
mutation(s) with a wildtype subtype C CN (#), are shown bold for each drug.
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wild-type subtype B and C (data not shown).
As observed with subtype B, the CN mutations in subtype C
increased RTI drug resistance levels. In POL backgrounds contain-
ing similar TAMs or classical NNRTI mutations, the CN from each
patient in general increased AZT and NNRTI resistance levels. The
contribution of the identiﬁed CN mutations to drug resistance
was further conﬁrmed by reversion mutation experiments, which
decreased the levels of AZT resistance up to six fold. Interestingly,
the mutations in the patients’ CNs were also able to increase
resistance to ETR, in a POL containing three NNRTI resistance
mutations. We have previously shown that CN mutations in
subtype B exhibit dual resistance to NRTIs and NNRTIs especially
in the context of a POL containing NNRTI mutations (Nikolenko
et al., 2010). These results are also in agreement with Gupta et al.
which showed enhanced ETR resistance with CN mutations T369Iand N348I in the presence of speciﬁc NNRTI-containing POL
domains (Gupta et al., 2011). Brehm et al. conﬁrmed enhanced
ETR resistance for N348I with NNRTI-containing POLs (Brehm
et al., 2012a). Furthermore, CN mutation E399D was also found to
be associated with ETR resistance (Poveda et al., 2008), and T386A
CN mutation was selected for ETR resistance during in vitro
selection studies (Vingerhoets et al., 2005). Recently, McCormick
et al. showed that N348I increases resistance across different
subtypes and increases ETV (2 fold), NVP (5 fold) and EFV
(3–5 fold) resistance (McCormick et al., 2011), Furthermore, it
was shown that N348I may be selected in the presence of NVP or
EFV drug therapy (Price et al., 2010). These studies highlight the
importance of CN mutations in clinical NNRTI resistance.Conclusions
Overall, these data show that subtype-C acquires mutations in
the CN of RT that contribute to both NRTI and NNRTI resistance.
With growing numbers of patients infected with subtype C
receiving ART, it is becoming increasingly important to under-
stand the baseline polymorphisms in the non-B subtypes that
contribute to drug resistance, and the pattern and emergence of
drug resistance mutations in response to therapy. Reports of drug
resistance mutations and patterns in non-B subtypes (reviewed in
(Martinez-Cajas et al., 2009; Martinez-Cajas et al., 2008)) still do
not include mutations downstream of POL in RT. Our studies
show that CN mutations can enhance RTI resistance in subtypes B
and C, implying that perhaps CN mutations contribute to
enhanced RTI resistance in all subtypes. Therefore, inclusion of
CN mutations in resistance testing is likely to facilitate design of
drug regimens that are speciﬁcally directed to the individual
patients’ viral genotypes. Furthermore, identiﬁcation of unique
CN mutations will also be useful for novel RT drug design and
understanding of the biochemical mechanisms of RT resistance to
antiviral drugs.Material and methods
Patient samples
Plasma samples from seven treatment-experienced HIV-posi-
tive patients regularly followed at the HIV/AIDS Unit of Universi-
dade Federal de Rio Grande, Southern Brazil, were collected. All
patients signed a written consent to participate in the study, and
the Institutional Ethics Committee (CEPAS) approved the study.
Results from single genome sequencing showed three patients to
contain no RTI mutations in the POL domain relative to wild-type
subtype C (MJ4, GenBank AF321523), and therefore were
excluded from these studies as their RT represented a wild-type
genotype. The majority genotypes from the remaining four
patients (P1, P2, P3, and P5) were used in this study. Viral loads
for P1, P2, and P3 were 4789, 1925, and 153,453 copies/ml,
respectively. Viral load for P5 was not determined. P1 received
AZT, 3TC and NFV treatment. P2 received AZT, 3TC, NFV/TDF and
3TCþATV/R treatment. P3 received AZT, 3TC, TDF and EFV
treatment. P5 received AZT, 3TC and EFV treatment.
Plasmids, cloning, and mutagenesis
pHCMV-G expresses the G glycoprotein of vesticular stomatitis
virus (VSV-G) (Yee et al., 1994). Construction of vector pHL[WT]
was previously described (Nikolenko et al., 2007) and will be
referred to as pHL[B-WT] in this paper to specify that it is a wild-
type subtype B genotype. pHL[C-WT] contains the POL, CN, and
K.A. Delviks-Frankenberry et al. / Virology 435 (2013) 433–441 439RH from wild-type subtype C subcloned into pHL[B-WT] (Fig. 2A).
All three constructs express the ﬁreﬂy luciferase reporter gene
and all of the HIV-1 proteins except Nef and Env. Vectors pHL[B-
TAMs] and pHL[C-TAMs] were created by introducing NRTI
resistance mutations D67N, K70R, T215Y/F, and K219Q into
pHL[B-WT] and pHL[C-WT], respectively (Fig. 2B and C). Site-
directed mutagenesis was carried out using the QuikChange Site-
Directed Mutagenesis Kit (Stratagene), and the presence or
absence of each mutation was veriﬁed by DNA sequencing.
Single genome sequencing
Viral RNA was extracted from patient plasma samples and used
for single genome sequencing as previously described (Kearney et al.,
2008). Primers were modiﬁed to speciﬁcally amplify the entire
subtype C RT. Round 1 PCR primers were ExtC for 50–AAAGCCAG-
GAATGGATGGCCC-30 and ExtCrev 50–CTCACTAGCCATTGCTCTCC-30.
Round 2 nested PCR primers were Msc1-1for 50–CCCAAAAGTTAAA-
CAATGGCCATTGAC-30 and ClaRev 50–CTTCTTGGGCCTTATCGATTCC-
30, which contained unique Msc I and Cla I restriction sites, respec-
tively, to use for cloning into pHL[WT]. Positive PCR reactions were
subcloned and sequenced and the majority genotype from each
patient was used for cloning and drug resistance analysis.
Antiviral drugs
AZT and 20,30-didehydro-30-dideoxythymidine (d4T) were
obtained from Sigma-Aldrich . Inhibitors nevirapine (NVP), efa-
virenz (EFV) and etravirine (ETR) and tenofovir (TDF) were
obtained from the NIH AIDS Research & Reference Reagent
Program. Delavirdine (DLV) and 20,30-dideoxy-30-thiacytidine
(3TC) were purchased from Movarek Biochemicals.
Cells, transfection, virus production, and drug susceptibility assays
Human embryonic kidney 293T cells (American Type Culture
Collection) were maintained at 5% CO2 and 37 1C in Dulbecco’s
modiﬁed Eagle’s medium (CellGro) supplemented with 10% FCS
(HyClone), penicillin (50 U/ml; Gibco) and streptomycin (50 mg/
ml; Gibco). To produce virus, 293T cells were transfected with
each vector using calcium phosphate precipitation (Clontech) in
the presence of pHCMV-G . Virus was harvested 48-h later, spun
to remove cellular debris, ﬁltered through a Millex GS 0.45 mm-
pore-size ﬁlter (Nalgene), and concentrated 25-fold by ultracen-
trifugation. Single-cycle drug susceptibility assays were per-
formed as previously described (Nikolenko et al., 2005). Final
drug EC50 data represents the standard error of the mean of at
least two replicates from three independent experiments.
Statistical analysis
Student’s t-test was used to determine statistically signiﬁcant
differences for EC50 data (SIGMAPLOT 8.0 software). Chi-Square and
Fisher’s exact tests were performed using statistical tools freely
available online (http://www.quantitativeskills.com/sisa/statistics/).Acknowledgments
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